These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 21944191)
1. Utility of the PET-CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results. Cortés Romera M; Gámez Cenzano C; Caresia Aróztegui AP; Martín-Comín J; González-Barca E; Ricart Brulles Y; Palacios Abufón A; Robles Barba J; Rodríguez-Bel L; Rossi Seoane S; Fernández de Sevilla A Rev Esp Med Nucl Imagen Mol; 2012; 31(3):135-41. PubMed ID: 21944191 [TBL] [Abstract][Full Text] [Related]
2. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734 [TBL] [Abstract][Full Text] [Related]
3. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542 [TBL] [Abstract][Full Text] [Related]
4. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma. Wu X; Pertovaara H; Korkola P; Vornanen M; Järvenpää R; Dastidar P; Eskola H; Kellokumpu-Lehtinen PL Acta Oncol; 2014 Aug; 53(8):1093-9. PubMed ID: 24960581 [TBL] [Abstract][Full Text] [Related]
5. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440 [TBL] [Abstract][Full Text] [Related]
6. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. Martelli M; Ceriani L; Zucca E; Zinzani PL; Ferreri AJ; Vitolo U; Stelitano C; Brusamolino E; Cabras MG; Rigacci L; Balzarotti M; Salvi F; Montoto S; Lopez-Guillermo A; Finolezzi E; Pileri SA; Davies A; Cavalli F; Giovanella L; Johnson PW J Clin Oncol; 2014 Jun; 32(17):1769-75. PubMed ID: 24799481 [TBL] [Abstract][Full Text] [Related]
8. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation. Qiao W; Zhao J; Wang C; Wang T; Xing Y Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658 [TBL] [Abstract][Full Text] [Related]
9. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era. Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757 [TBL] [Abstract][Full Text] [Related]
10. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications]. Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527 [TBL] [Abstract][Full Text] [Related]
11. Prognostic Importance of Bone Marrow Uptake on Baseline Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875 [TBL] [Abstract][Full Text] [Related]
13. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197 [TBL] [Abstract][Full Text] [Related]
15. [Neurolymphomatosis: diagnosis of extension and assessment of response to treatment with PET-CT]. Durán C; Infante JR; Serrano J; Rayo JI; García L; Domínguez ML; Sánchez R Rev Esp Med Nucl; 2009; 28(6):295-8. PubMed ID: 19864049 [TBL] [Abstract][Full Text] [Related]
16. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911 [TBL] [Abstract][Full Text] [Related]
17. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Yang DH; Ahn JS; Byun BH; Min JJ; Kweon SS; Chae YS; Sohn SK; Lee SW; Kim HW; Jung SH; Kim YK; Kim HJ; Bom HS; Lee JJ Ann Hematol; 2013 Apr; 92(4):471-9. PubMed ID: 23238895 [TBL] [Abstract][Full Text] [Related]
18. Diffuse pulmonary uptake on FDG-PET with normal CT diagnosed as intravascular large B-cell lymphoma: a case report and a discussion of the causes of diffuse FDG uptake in the lungs. Wagner T; Brechemier D; Dugert E; Le Guellec S; Julian A; Hitzel A; Beyne-Rauzy O Cancer Imaging; 2012 Jan; 12(1):7-12. PubMed ID: 22275725 [TBL] [Abstract][Full Text] [Related]
19. [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients]. Oriuchi N; Higuchi T; Endo K; Tsukamoto N; Matsuda H; Kuji I; Murakami K; Nakajima K Kaku Igaku; 2009 Jun; 46(2):96-9. PubMed ID: 19637820 [TBL] [Abstract][Full Text] [Related]
20. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]